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Ubiquitin-dependent processes are critical for propagating antiviral defense signals during viral 
infection. In this issue, Zeng et al. (2010) describe how viral RNA and unanchored ubiquitin chains 
conspire to promote activation of RIG-I and the host cell’s antiviral transcriptional program.Detection of, and defense from, patho-
gens represents a major challenge for cel-
lular systems, and elaborate mechanisms 
have evolved to sense common foreign 
agents and to promote the production of 
molecules that fight the invader. One such 
mechanism uses retinoic-acid-inducible 
gene-I (RIG-I) like receptors (RLRs) to 
sense viral RNA molecules and initiate 
a signaling cascade that involves bind-
ing of RLRs to the MAVS (mitochondrial 
antiviral signaling) protein. This leads to 
MAVS-dependent activation of TANK-
binding kinase (TBK1), which phosphory-
lates interferon regulatory factor 3 (IRF3), 
promoting its dimerization and transloca-
tion to the nucleus. MAVS also promotes 
activation of Iκ-B kinase (IKK), which pro-
motes the nuclear import of the transcrip-
tion factor NF-κB. IRF3 and NF-κB then 
induce transcription of genes involved in 
antiviral defense (Moore and Ting, 2008). 
Multiple steps in the pathway, including 
activation of TBK1 and IKK, as well as 
nuclear import of NF-κB, are controlled by 
the ubiquitin system through both regula-
tory and degradative mechanisms (Bhoj 
and Chen, 2009). In addition, ubiquitina-
tion of RIG-I itself seems to promote the 220 Cell 141, April 16, 2010 ©2010 Elsevier antiviral response (Gack et al., 2007). But 
how this occurs, how viral RNA serves as 
a trigger, or how RIG-I signals to MAVS 
are not clear. Using an elegant in vitro sys-
tem that recapitulates the major steps in 
RNA-dependent activation of IRF3 (Zeng 
et al., 2009), Zeng and colleagues show in 
this issue of Cell that RIG-I activation by 
RNA promotes recruitment of unanchored 
lysine 63 (K63)-linked ubiquitin chains to 
the caspase recruitment domains (CARDs) 
of RIG-I independent of ubiquitin conjuga-
tion to RIG-I (Zeng et al., 2010). This estab-
lishes that unanchored ubiquitin chains 
together with RIG-1 form a potent viral 
RNA sensor that directly communicates 
with MAVS to promote IRF3 activation 
(Zeng et al., 2010), ultimately resulting in 
an antiviral response.
Polyubiquitin chains linked through 
specific lysine residues on ubiquitin con-
fer different molecular fates on the conju-
gated substrate (Ye and Rape, 2009). In 
response to a viral infection, K63-linked 
ubiquitin chains serve as scaffolds to 
activate downstream signaling kinases, 
including TBK1 and IKK, which activate 
IRF3 and NF-κB, respectively (Bhoj and 
Chen, 2009). Upstream of MAVS, the E3 Inc.ubiquitin ligase TRIM25 is necessary for 
interferon-β (IFN-β) production following 
viral infection, presumably after ubiquit-
ination and activation of RIG-I (Gack et al., 
2007). By recreating this signaling cascade 
in a cell-free system, Zeng et al. (2010) 
determined the necessary ubiquitin- and 
viral RNA-dependent triggers required for 
IRF3 activation. Mixing purified mitochon-
drial and cytoplasmic fractions from virally 
infected (but not uninfected) cells resulted 
in TBK1/IKKε-dependent dimerization 
of IRF3, a readout for pathway activation 
(Zeng et al., 2009) (Figure 1). Importantly, 
this signaling pathway was dependent on 
RIG-I, MAVS, and TRIM25, as depletion 
of any of these components blocked or 
reduced IRF3 activation (Zeng et al., 2010). 
Transfection of a viral RNA mimic into cells 
led to robust expression of IFN-β; how-
ever, incubation of the same RNA with 
purified RIG-I failed to activate IRF3 in the 
in vitro assay. Remarkably, incubation of 
purified RIG-I with the ubiquitin conjuga-
tion machinery and TRIM25, together with 
viral RNA, restored pathway activation in 
the absence of viral infection, establish-
ing the critical importance of ubiquitin 
chain formation for RIG-I activation. Con-
figure 1. Ubiquitin and Antiviral Defense
Unanchored ubiquitin (Ub) chains promote RIG-I- and MAVS-dependent activation of IRF3 in response to viral infection. 
(A) Lysine 63 (K63)-linked ubiquitin chains are synthesized by an E1-E2-E3 ubiquitin conjugation system involving the E2 enzymes Ubc5 and Ubc13 and the E3 ubiq-
uitin ligase TRIM25. The deubiquitinating (Dub) enzyme USP5 normally promotes disassembly of unanchored ubiquitin chains. However, K63-linked ubiquitin chains 
can be assembled on retinoic-acid-inducible gene-I (RIG-I) using this ubiquitination machinery, with liberation of the assembled chains by an as yet unknown Dub. 
(B) RIG-I is inactive in the absence of viral RNA. But when viral RNA binds to the helicase domain of RIG-I, this triggers binding of pre-existing unanchored K63-linked 
ubiquitin chains to the N-terminal CARD domains of RIG-I. Activated RIG-I then interacts with the CARD domain of the mitochondrial membrane-associated protein 
MAVS. MAVS-dependent signaling leads to activation of the TBK1 and IKKε kinases, which phosphorylate IRF3 promoting its dimerization. IRF3 dimers are then trans-
located into the nucleus where they induce the expression of genes encoding proteins, such as interferon-β (IFN-β), that are involved in the response to viral infection.sistent with recent results demonstrating 
that K63-linked ubiquitin conjugation is 
required for IRF3 activation in vivo (Zeng 
et al., 2009), dimerization of IRF3 in vitro 
required ubiquitin containing lysine 63.
Although the E2 ubiquitin-conjugating 
enzyme Ubc13 can catalyze the assem-
bly of K63-linked ubiquitin chains, Ubc5 is 
also important for this process. Consistent 
with this, depletion of Ubc5 substantially 
reduced activation of IRF3 in vitro (Zeng et 
al., 2009) raising the possibility that resid-
ual activity was due to Ubc13. Zeng and 
colleagues now report that codepletion of 
the Ubc13 and Ubc5 paralogs fully inhib-
ited IRF3 pathway activation. Importantly, 
incubation of these enzymes individually 
with purified RIG-I restored IRF3 activa-
tion in a K63 ubiquitin-dependent manner. 
These findings indicate that either Ubc13 
or Ubc5 can assemble K63-linked ubiq-
uitin chains that promote IRF3 activation 
in vitro, although these proteins appear 
to function redundantly in vivo (Figure 1A). 
But how does ubiquitin chain synthesis 
promote activation of the IRF3 pathway?
RIG-I contains a C-terminal ATP-depen-
dent RNA helicase domain that recog-
nizes the uncapped 5′-triphosphorylated 
single-stranded RNAs of viruses, as well 
as two N-terminal CARDs that bind to the CARD domain of MAVS (Yoneyama and 
Fujita, 2008) (Figure 1B). RIG-I is known 
to be ubiquitinated by TRIM25 on lysine 
172 in the second CARD domain, and this 
residue is necessary for RIG-I activation 
(Gack et al., 2007). To examine the poten-
tial role of RIG-I ubiquitination in vitro, 
Zeng et al. (2010) took advantage of the 
fact that the N-terminal CARD domains of 
RIG-I can bypass the requirement for viral 
RNA in pathway activation. Incubating the 
N-terminal CARD domains of RIG-I with 
E2-conjugating enzymes and TRIM25, 
which catalyze assembly of K63-ubiquitin 
chains, resulted in MAVS-dependent acti-
vation of IRF3, but other E2/E3 pairs that 
catalyze K48-linked or linear ubiquitin 
chains did not. Given previous findings 
(Gack et al., 2007), it seemed reasonable to 
assume that activation required building of 
K63-linked polyubiquitin chains on lysine 
172 in RIG-I. However, Zeng et al. provide 
an alternative mechanism by demonstrat-
ing that unanchored K63-linked (but not 
K48-linked) ubiquitin chains could pro-
mote pathway activation independently of 
the ubiquitin conjugation system by bind-
ing directly to the CARD domains of RIG-I. 
Indeed, treating RIG-I CARD domains 
isolated from human cells with a deubiq-
uitinating enzyme that strips anchored Cell chains from RIG-I failed to block pathway 
activation in vitro because unanchored 
K63-linked ubiquitin chains bound to the 
CARD domains were protected from dis-
assembly, thereby maintaining RIG-I in an 
active form. Moreover, a viral RNA mimic 
together with unanchored K63-linked 
ubiquitin chains and full-length RIG-I pro-
moted pathway activation, revealing that 
binding of RNA to RIG-I is a prerequisite 
for binding of ubiquitin chains to the RIG-I 
CARD domains. So why can’t RIG-I lack-
ing lysine 172 activate the IRF3 pathway? 
Zeng and colleagues demonstrate that 
this residue is required for ubiquitin chains 
to bind to RIG-I.
Given the abundance of ubiquitin iso-
peptidases, unanchored ubiquitin chains 
are thought to be rare in cells. Thus, the 
question is whether unanchored chains 
activate RIG-I in vivo. To address this, the 
authors purified ubiquitin chains from RIG-I 
N-terminal CARD domains in mammalian 
cells using selective thermal denaturation 
techniques and found that these chains 
could activate the pathway when reintro-
duced into the cell-free system together 
with the RIG-I CARD domains. Zeng et al. 
used two approaches to provide strong 
evidence that the active ubiquitin chains 
are unanchored. First, the deubiquitinating 141, April 16, 2010 ©2010 Elsevier Inc. 221
enzyme USP5, which selectively cleaves 
unanchored chains (Figure 1A; Reyes-
Turcu et al., 2006), destroyed the abil-
ity of chains released from RIG-I CARD 
domains to promote pathway activation. 
Second, these chains were charged by 
the E1 ubiquitin-activating enzyme, which 
requires a free C-terminal glycine found in 
unanchored ubiquitin chains for charging.
The new work of Zeng et al. establishes 
a model in which RIG-I first senses a viral 
infection by binding to viral RNA through 
its RNA helicase domain, thereby expos-
ing the tandem N-terminal CARD domains 
(Figure 1B). The exposed CARD domains 
then associate with unanchored K63-
linked ubiquitin chains, thereby facilitating 
recognition of MAVS and activation of the 
IRF3 pathway. Although Zeng et al. (2010) 
convincingly demonstrate that unanchored 
K63-linked ubiquitin chains activate RIG-I, 
the underlying mechanism remains to be 
elucidated. As the CARD domain of MAVS 
cannot bind to ubiquitin directly, one pos-
sibility is that binding of ubiquitin to RIG-I 
reveals a surface within the RIG-I CARD 
domains that then interacts with MAVS. 
The origin and abundance of the unan-
chored chains also remains a mystery, 222 Cell 141, April 16, 2010 ©2010 Elsevier I
The plant toxin ricin and the bacte-
rial Shiga toxins are among the most 
toxic compounds known to man. 
Shiga toxins, produced by patho-
genic Escherichia coli and Shigella 
dysenteriae, cause dysentery in mil-
lions of people around the world every 
year; and, ricin, produced by the cas-
tor bean (Ricinus communis), gained 
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To inhibit protein synthesis and in
the cell through the endocytic an
identify two small-molecule inhib
and Shiga toxins and protect micalthough Zeng and coworkers provide 
data implicating TRIM25. It remains pos-
sible that a K63-linked ubiquitin chain is 
constructed on RIG-I itself (or on another 
substrate), and that this chain is then 
selectively liberated through the action 
of an unknown deubiquitinating enzyme 
(Figure 1). Because introduction of the RIG 
CARD domains into cells is sufficient to 
activate the IRF3 pathway in the absence 
of a viral RNA trigger, it appears that unan-
chored chains are not limiting within the 
cell. Further, the authors estimate, based 
on the quantity of chains purified with 
RIG-I CARD domains, that there may be 
as many as 6000 unanchored K63-linked 
chains per cell. Although viral infection may 
alter the abundance of unanchored chains, 
it seems plausible that sufficient unan-
chored chains pre-exist. Thus, once trig-
gered by viral RNA, the downstream cas-
cade may be immediately initiated without 
an additional regulatory step. The authors 
estimate that RIG-I can sense less than 20 
molecules of viral RNA or K63-linked ubiq-
uitin chains, making it an exquisite sensor 
of viral infection. The powerful in vitro sys-
tem developed and improved by Zeng et 
al. sets the stage for a more comprehen-nc.
notoriety when it was used to assas-
sinate the Bulgarian journalist Georgi 
Markov in 1978. There are currently 
no known antidotes to Shiga toxin or 
ricin, and the potential use of ricin in 
a bioterror attack is of major concern. 
In this issue of Cell, Stechmann et al. 
(2010), now identify two small mol-
ecules that protect cells against Shiga 
 a Retrograde R
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duce cell death, plant ricin toxin 
d retrograde secretory pathway
itors that selectively block endo
e from ricin’s deadly effects.sive analysis of how ubiquitin chains work 
with RIG-I to protect cells against foreign 
invaders and whether unanchored ubiq-
uitin chains are involved in other signaling 
pathways. The answer to these questions 
may just be in the CARDs.
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